YN440342 XL228 898280-07-4

XL228 is a protein kinase inhibitor with IC50 of 5 nM, 1.4 nM, 3.1 nM, 1.6 nM, 6.1 nM and 2 nM for wild-type ABL kinase, ABL T315I, Aurora A, IGF-1R, SRC and LYN...

YN440143 CZC-8004 916603-07-1

CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, includingABLkinase.

YN440040 Nilotinib monohydrochloride m... 923288-90-8

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent againstBCR-ABL, and is active against many BCR-ABL mutants.

YN440339 Radotinib 926037-48-1

Radotinib(IY-5511) is a novel and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34nM for wild-type BCR-ABL1 kinase.

YN440187 Ponatinib 943319-70-8

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37nM, 1.1nM, 1.5nM, 2.2nM, and 5.4nM forAbl,PDGFRα,VEGFR2,FGFR1, and Src, respectively.

YN440082 KW-2449 1000669-72-6

KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.

YN440241 Rebastinib 1020172-07-9

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to se...

YN440322 Imatinib D8 1092942-82-9

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

YN440323 Imatinib D4 1134803-16-9

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

YN440033 GZD856 1257628-64-0

GZD856 is a potent and orally bioavailablePDGFRα/βinhibitor with IC50s of 68.6 and 136.6nM, respectively.GZD856 is also aBcr-AblT315Iinhibitor with IC50s of 19.9 and 15.4 nM for Bcr-Abl and T315I mutant....

YN440337 GZD824 1257628-77-5

GZD824 (HQP1351) is an orally bioavailable pan-Bcr-Ablinhibitor with potency against a wide range of Bcr-Abl mutants and the native enzyme (IC50=0.34nM). GZD824 has antitumor activity.

YN440338 GZD824 dimesylate 1421783-64-3

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

YN440090 Asciminib 1492952-76-7

Asciminib(ABL001) is a potent and selective allosteric ABL1 inhibitor with dissociation constant (Kd) of?0.5-0.8?nM and selectivity to the myristoyl pocket of ABL1.

YN440045 Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.